Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that has demonstrated significant efficacy for weight management in clinical trials. The STEP (Semaglutide Treatment Effect in People with obesity) program established the dose-response relationship across multiple pivotal trials. This guide covers the complete dosing schedule from initiation through maintenance.
Semaglutide activates GLP-1 receptors in the hypothalamus, reducing appetite and food intake. It delays gastric emptying, increases satiety signaling, and modulates reward pathways associated with food consumption. These combined mechanisms produce sustained caloric deficit without requiring active dietary restriction.
Wegovy (semaglutide 2.4 mg) is the only FDA-approved formulation specifically for chronic weight management. The dose escalation schedule is designed to minimize gastrointestinal adverse effects during initiation.
| Phase | Week | Dose | Frequency | Purpose |
|---|
| Initiation | 1–4 | 0.25 mg | Once weekly | GI tolerability titration |
| Escalation 1 | 5–8 | 0.5 mg | Once weekly | First therapeutic dose |
| Escalation 2 | 9–12 | 1.0 mg | Once weekly | Intermediate dose |
| Escalation 3 | 13–16 | 1.7 mg | Once weekly | Pre-maintenance |
| Maintenance | 17+ | 2.4 mg | Once weekly | Full maintenance dose |
- Minimum 4 weeks at each dose level before escalation
- Delay escalation if gastrointestinal symptoms (nausea, vomiting, diarrhea) are present
- Target maintenance dose is 2.4 mg weekly for maximum weight loss efficacy
- Minimum effective dose for weight loss is 1.0 mg weekly (intermediate efficacy)
| Parameter | Semaglutide 2.4 mg | Placebo |
|---|
| Mean weight loss (68 weeks) | −14.9% (−15.3 kg) | −2.4% (−2.6 kg) |
| ≥5% weight loss responders | 83.5% | 31.1% |
| ≥10% weight loss responders | 66.1% | 12.0% |
| ≥15% weight loss responders | 47.9% | 5.0% |
| ≥20% weight loss responders | 30.0% | 1.2% |
| Systolic BP reduction | −6.2 mmHg | −1.5 mmHg |
| HbA1c reduction | −0.29% | +0.08% |
| Parameter | Semaglutide 2.4 mg | Placebo |
|---|
| Mean weight loss (68 weeks) | −9.6% | −3.4% |
| HbA1c reduction | −1.6% | −0.4% |
| ≥5% weight loss | 68.8% | 28.5% |
| Parameter | Semaglutide 2.4 mg + IBT | Placebo + IBT |
|---|
| Mean weight loss (68 weeks) | −16.0% | −5.7% |
| ≥5% weight loss | 86.6% | 47.6% |
| ≥15% weight loss | 55.8% | 13.2% |
| Parameter | Semaglutide 2.4 mg | Placebo |
|---|
| Mean weight loss (104 weeks) | −15.2% | −2.6% |
| Weight regain after discontinuation | +6.9% (post-treatment) | — |
| Parameter | Continued Semaglutide | Switched to Placebo |
|---|
| Weight change after 68 weeks | −17.4% (total) | −5.0% (regained after withdrawal) |
Ozempic (semaglutide) is approved for type 2 diabetes but is frequently prescribed off-label for weight management. The dosing differs from Wegovy:
| Week | Dose | Purpose |
|---|
| 1–4 | 0.25 mg weekly | Initiation |
| 5–8 | 0.5 mg weekly | First maintenance |
| 9–12 | 1.0 mg weekly | Intermediate |
| 13+ | 2.0 mg weekly | Maximum dose |
Note: Ozempic maximum approved dose is 2.0 mg weekly — lower than Wegovy’s 2.4 mg. Weight loss efficacy is dose-dependent, with greater losses at higher doses.
Oral semaglutide at 14 mg daily has demonstrated modest weight loss in the PIONEER trials:
| Dose | Mean Weight Loss | Clinical Context |
|---|
| 3 mg daily | −0.1 kg | Non-therapeutic |
| 7 mg daily | −0.7 kg | Diabetic population |
| 14 mg daily | −1.5 kg | Maximum oral dose |
Oral semaglutide produces significantly less weight loss than injectable 2.4 mg, limiting its utility for obesity management.
| Dose | Approximate Weight Loss | Efficacy Category |
|---|
| 0.25 mg weekly | 2–3% | Initiation only |
| 0.5 mg weekly | 4–6% | Mild |
| 1.0 mg weekly | 6–8% | Moderate |
| 1.7 mg weekly | 8–10% | Substantial |
| 2.4 mg weekly | 12–16% | Maximum |
STEP 4 demonstrated that patients who discontinued semaglutide regained approximately two-thirds of lost weight over one year. Long-term or indefinite treatment is generally required to maintain weight loss.
- 2.4 mg weekly: Standard maintenance for maximum efficacy
- 1.7 mg weekly: Alternative if 2.4 mg not tolerated (STEP 5 showed comparable results)
- 1.0 mg weekly: Minimum dose with meaningful weight loss maintenance
| Symptom | Management |
|---|
| Persistent nausea | Delay dose escalation; maintain current dose until resolution |
| Severe GI symptoms | Consider dose reduction by one step |
| Pancreatitis (suspected) | Discontinue immediately |
| Gallbladder disease | Evaluate risk-benefit; may require discontinuation |
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” NEJM 2021;384:989-1002.
- Davies MJ, et al. “Semaglutide 2.4 mg once weekly in participants with type 2 diabetes and obesity (STEP 2).” Diabetes Obes Metab 2022;24:2128-2139.
- Wadden TA, et al. “Semaglutide 2.4 mg and intensive behavioral therapy for obesity (STEP 3).” JAMA 2021;325:1329-1338.
- Rubino D, et al. “Effect of continued subcutaneous semaglutide vs placebo on weight maintenance (STEP 4).” JAMA 2022;327:534-545.
